VEGFA and neoplasm: Indeed, linking an antibody to the anti-vascular endothelial growth factor (VEGF) pegaptanib aptamer extended the in vivo pharmacokinetic of the aptamer without affecting its binding affinity and, on the other hand, the aptamer part of the monospecific immune conjugate penetrated deep into the tumor while anti-VEGF antibody did not.